Advances in immunotherapy in EGFR-mutated non-small cell lung cancer

Abstract:

In patients with non-small cell lung cancer（NSCLC） with EGFR driver mutation，EGFR-TKIs is the standard treatment but acquired resistance is inevitable. There is currently no standard treatment for first-line EGFR-TKIs-resistant NSCLC patients. Immunotherapy combined with platinum-containing double-drug chemotherapy and vascular endothelial growth factor inhibitors has shown some efficacy. This paper reviews the research on different programmed cell death 1（PD-1）/PD-1 ligand（PD-L1） immune checkpoint inhibitors in the treatment of NSCLC patients with EGFR mutation，and explores improved treatment modalities for NSCLC patients with EGFR mutation.